We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Argent Biopharma Limited | LSE:RGT | London | Ordinary Share | AU0000326647 | ORD NPV (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 21.50 | 20.00 | 23.00 | 21.50 | 21.50 | 21.50 | 6,329 | 08:00:21 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMRGT RNS Number : 2090T ReGen Therapeutics PLC 02 June 2009 2/06/2009 For immediate release AIM/PLUS: RGT ReGen Signs Exclusive Distribution Agreement for Colostrinin(TM) in Poland ReGen Therapeutics Plc ('ReGen' or the 'Company') announces that it has today signed an agreement with Tagerr Polska* for the exclusive distribution and marketing of its nutritional supplement Colostrinin(TM) in Poland. This comes after a period of test - marketing by Tagerr during which Tagerr also satisfied all necessary regulatory requirements to import/distribute the product in Poland. To date Colostrinin(TM) is marketed in the US, Canada and Australia under the brand name CogniSure(TM) ** and in Cyprus under the brand name Cognase(TM) *** as a nutritional supplement to 'support healthy brain ageing and cognition in humans'. Commenting on this agreement Percy Lomax, Chairman and Chief Executive Officer of ReGen said : 'Poland is the country where Colostrinin(TM) was first discovered and we know from various communications that there is significant knowledge of the product in Poland. Poland has a population of 38 million people and a Gross Domestic Product per Capita of $11,072. As such both Tagerr Polska and ourselves are optimistic that the volume of sales here should be significant.' *Tagerr Polska is an affliate of Tagerr a professional services and trading company established in Köln, Germany. In operation since 1995, Tagerr has enjoyed considerable successes in marketing and distributing consumer products, including food supplements, in central Europe and Germany. (www.cognisure.eu) **Colostrinin(TM) for use as a human nutraceutical is licensed in North America and Australasia to Metagenics Inc. of San Clemente, California (www.metagenics.com). *** Colostrinin(TM) is distributed in the Republic of Cyprus by Golgi Pharmaceuticals Ltd (www.healthybrainaging.com) For further information: Percy Lomax ReGen Therapeutics Plc Tel No 020 7153 4920 Roland Cornish/Felicity Geidt Beaumont Cornish Limited Tel No 020 7628 3396 Nick Bealer/David Scott Alexander David Tel No 020 7448 9820 Notes to Editors: Colostrinin(TM) is derived from colostrum a mammal's first milk after birth and is produced in a production line in S Dakota, freeze dried in Oregon and tabletted at Metagenics Inc plant in California. Metagenics are the distributors in North America and Australia. If full production and sales were achieved on North American margins revenue to the Company would be $10 million before relatively low head office expenses. It would be possible, by spending around another $550,000 to bring production facilities up to a level to generate revenue of around $50 million. Colostrinin(TM) has been available in the professional channel of the healthcare market in North America and Australia for over a year. Although achieving professional awareness and endorsement was a necessary first step, retail distribution, was always and remains our objective. This information is provided by RNS The company news service from the London Stock Exchange END MSCCKBKQDBKDOAK
1 Year Argent Biopharma Chart |
1 Month Argent Biopharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions